Author name: Leonardo Arias

The proposed rule aims to tamp down on unwieldy price data files and change how some prices are reported.

The request for information comes as the Trump administration has largely taken a deregulatory stance on AI, in a bid to avoid hampering the technology’s rollout.

Leerink analysts hailed the deals as a sign that President Trump “is unlikely to attack the industry in 2026.”

Con el calor del verano cada vez más intenso en muchas regiones de España, elegir el sistema de enfriamiento adecuado se convierte en una decisión clave para el confort y el bolsillo. Dos opciones muy populares son el aire acondicionado y el enfriador de aire (también con …

Ceralasertib is part of AstraZeneca’s ambitious plan to hit $80 billion in revenue by 2030.

The biologics center director reportedly became personally involved after the team reviewing the rare blood disorder filing asked for an extension to the CNPV-accelerated timeline.

The biotech, which has a deal with Eli Lilly worth as much as $1.1 billion, is developing two targeted radiopharmaceuticals from its miniprotein radioconjugate platform.

Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.

The second half finished strong after two tumultuous years. What will 2026 bring for the biotech sector?

Pfizer and Metsera, Sarepta and uniQure made the list with dramatic tales. The other two spots went to the regulatory challenges facing biopharma under the new administration, especially in the vaccines sector.